Based on current clinical data, concurrent CRT with maintenance PD-1/PD-L1 inhibition in inoperable stage III NSCLC is a safe and effective multimodal approach with unprecedented median PFS ranging from 16 to 20 months und 2-year OS rates of 60 to 70%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.